Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
| Author | :
|
|---|---|
| Abstract | :
Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. |
| Year of Publication | :
2017
|
| Journal | :
The New England journal of medicine
|
| Volume | :
376
|
| Issue | :
16
|
| Number of Pages | :
1527-1539
|
| Date Published | :
2017
|
| ISSN Number | :
0028-4793
|
| URL | :
https://www.nejm.org/doi/10.1056/NEJMoa1701488?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov
|
| DOI | :
10.1056/NEJMoa1701488
|
| Short Title | :
N Engl J Med
|
| Download citation |